MBA MD - Novocure Chief Officer
| NVCR Stock | USD 11.32 0.25 2.16% |
Executive
MBA MD is Chief Officer of Novocure
| Age | 51 |
| Address | Neuhofstrasse 21, Baar, Switzerland, 6340 |
| Phone | 44 15 3475 6700 |
| Web | https://www.novocure.com |
Novocure Management Efficiency
The company has return on total asset (ROA) of (0.0864) % which means that it has lost $0.0864 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4807) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 08/03/2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 08/03/2025, Non Currrent Assets Other is likely to grow to about 15.3 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michele Allegretto | Glaukos Corp | N/A | |
| Abigail BA | Axon Enterprise | N/A | |
| Andreas Henke | Inspire Medical Systems | N/A | |
| Blair Tripodi | Masimo | 51 | |
| Christine Gebski | Repligen | 56 | |
| Stephen Murphy | Guardant Health | N/A | |
| Ivan Lubogo | Inspire Medical Systems | N/A | |
| Zarak Khurshid | Guardant Health | N/A | |
| Ezgi Yagci | Inspire Medical Systems | N/A | |
| Neil Whitfield | Repligen | N/A | |
| Catherine Szyman | Masimo | 58 | |
| Keith Robinson | Repligen | N/A | |
| Diane Biagianti | Glaukos Corp | 62 | |
| Elizabeth Hart | Axon Enterprise | N/A | |
| Eli Kammerman | Masimo | N/A | |
| Jane Rady | Glaukos Corp | 77 | |
| Paul Hataishi | Masimo | 50 | |
| Robert Giglio | HubSpot | N/A | |
| Jason Garland | Repligen | 51 | |
| Erik Lapinski | Axon Enterprise | N/A | |
| Terilyn Monroe | Guardant Health | 58 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0864 |
Novocure Leadership Team
Elected by the shareholders, the Novocure's board of directors comprises two types of representatives: Novocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novocure. The board's role is to monitor Novocure's management team and ensure that shareholders' interests are well served. Novocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barak BenArye, General Counsel | ||
| William Burke, Chief Officer | ||
| Frank Leonard, Executive Oncology | ||
| Christoph Brackmann, Chief Officer | ||
| Asaf Danziger, CEO and Director | ||
| Uri MD, Chief Officer | ||
| Piet MD, Head VP | ||
| Pritesh Shah, Chief Commercial Officer | ||
| Ashley Cordova, Chief Officer | ||
| Moshe Giladi, Chief Officer | ||
| Wilhelmus Groenhuysen, Chief Officer | ||
| Pr MD, Founder CTO | ||
| MBA MD, Chief Officer | ||
| Ingrid Goldberg, VP Relations | ||
| Barak Arye, General Counsel | ||
| Mukund Paravasthu, Chief Officer | ||
| William Doyle, Executive Chairman | ||
| Michael Puri, Chief Officer |
Novocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0864 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 1.05 B | ||||
| Shares Outstanding | 111.8 M | ||||
| Shares Owned By Insiders | 9.81 % | ||||
| Shares Owned By Institutions | 84.72 % | ||||
| Number Of Shares Shorted | 4.93 M | ||||
| Price To Earning | 721.15 X |
Pair Trading with Novocure
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novocure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novocure will appreciate offsetting losses from the drop in the long position's value.Moving against Novocure Stock
| 0.76 | SSY | SunLink Health Systems | PairCorr |
| 0.7 | MGRM | Monogram Orthopaedics | PairCorr |
| 0.67 | FIGS | Figs Inc Earnings Call This Week | PairCorr |
| 0.51 | HSCSW | Heart Test Laboratories | PairCorr |
| 0.39 | DH | Definitive Healthcare Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Novocure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novocure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novocure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novocure to buy it.
The correlation of Novocure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novocure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novocure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novocure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.